Results 191 to 200 of about 16,480,514 (312)

Digital maturity index instrument development for primary health care in Indonesia: a sequential exploratory mixed-methods approach. [PDF]

BMC Health Serv Res
Anwar SJ, Sunjaya DK, Hilfi L, Rinawan FR, Ardisasmita MN, Diah Herawati DM.   +5 more
europepmc   +1 more source

Velopharyngeal Inadequacy-Related Quality of Life Assessment: The Instrument Development and Application Review. [PDF]

Front Surg, 2022
Chen N, Shi B, Huang H.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Key points in writing instrument development and psychometric evaluation reports. [PDF]

Rev Bras Enferm
Alizadeh M, Shahsavari H, Matourypour P.
europepmc   +1 more source

Erratum: Velopharyngeal Inadequacy-Related Quality of Life Assessment: The Instrument Development and Application Review. [PDF]

Front Surg, 2022
Frontiers Production Office.
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Cervical cancer screening uptake questionnaire (CCSTQ) for women: instrument development and validation. [PDF]

BMC Womens Health
Cheng N, Li X, Jin Z, Liu Y, Wang A.
europepmc   +1 more source

Plasmon Waveguide Resonance: Principles, Applications and Historical Perspectives on Instrument Development. [PDF]

Molecules, 2021
Rascol E, Villette S, Harté E, Alves ID.   +3 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Health and Social Care Managers' Competence in Knowledge Management Instrument: Development and Validation. [PDF]

Nurs Res Pract
Karsikas E, Meriläinen M, Koivunen K, Jarva E, Mikkonen K, Oikarinen A, Kääriäinen M, Jounila-Ilola P, Kanste O.   +8 more
europepmc   +1 more source